Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation

Table 3 Demographics and clinical characteristics of children with hepatitis B core antibody-positive allografts according to de novo hepatitis B virus infection status after living donor liver transplantation

Characteristics	De novo HBV infection (n = 5)	De novo HBV infection-free (n = 11)	P value
Donors
Age (yr)	38 (22-55)	30 (27-50)	0.223
Gender (n, M/F)	3/2	5/6	0.590
HBsAb (n, +/-)	4/1	10/1	0.541
Intrahepatic HBV DNA (n, +/-)	4/1	3/8	0.043
Recipients
Age (mo)	14 (10-18)	10 (8-43)	0.113
Gender (n, M/F)	2/3	6/5	0.590
PELD score	17 ± 3	17 ± 4	0.469
Preoperative HBcAb (n, +/-)	3/2	3/8	0.610
Preoperative HBsAb (n, +/-)	2/3	2/9	0.350
Preoperative ant-HBs/HBcAb (n, +/-)	2/3	7/4	0.377
Blood transfusion
RBC (mL)	420 ± 220	540 ± 172	0.216
FFP (mL)	416 ± 184	400 ± 183	0.908
Dose of prednisone/bodyweight (mg/kg)	46 ± 6	43 ± 8	0.318
Follow-up (mo)	17 (4-35)	14 (12-40)	0.356

M/F: Male/female; HBV: Hepatitis B virus; PELD: Pediatric model of end-stage liver disease; HBcAb: Hepatitis B core antibody; HBsAb: Hepatitis B surface antibody; RBC: Red blood cell; FFP: Fresh frozen plasma.